Novo’s oral amycretin could lead to more weight loss beyond 12 weeks, according to early-stage trial

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Mesoblast eyes accelerated approval filing for heart failure cell therapy – Pharmaceutical Technology

Share this article The indicated that the accelerated approval pathway could be an option for marketing due to positive clinical evidence. Image credit: Shutterstock/nobeastsofierce. Mesoblast’s

March 11, 2024

Study exposes the real weight gains of Australians to tackle overweight and obesity

There’s no doubt that Aussies love a good celebration. We’re all in when it comes to the weekend, and most of us can’t go past

July 28, 2023

Telling new stories can help people see the value of vaccines

Nearly nine in 10 Americans strongly believe in the overall value of childhood vaccines. Reflecting the value communities place on them, every state and the

June 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.